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INTRODUCTION
Amyloidosis is a pathological process encompassing a 
spectrum of disease that results from the extracellular 
deposition of fibrillar amyloid protein (1), which can 
involve any organ singly or in conjunction with other 
organs and can do so in the form of a focal, tumor-like 
lesion, or an infiltrative process (2). Although it is usually 
seen in a systemic form, 10-20% of cases can be localized 
(3). In both primary and secondary amyloidosis, the most 
commonly involved organ system is the gastrointestinal 
system, with the colon being the most frequently involved 
organ (2). Amyloidosis involving the liver is also common, 
and the radiologic findings are also nonspecific. Diffuse 
infiltration is the rule, which causes decreased attenuation 
at computed tomography (CT) and hepatomegaly (2). To our 
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knowledge, cases of amyloidosis involving the liver being 
presented as a mass have not been described previously. 
Here we report a case of primary hepatic amyloidosis that 
presented as a mass.
CASE REPORT
A 73-year-old woman was referred to our institution 
with general weakness and fever for a day. She had been 
treated with chemotherapy and radiation therapy over the 
last 20 years due to recurrent multiple myeloma in the right 
zygoma, sternum, and the posterior arch of T4 vertebra. 
Physical examination and routine laboratory test results 
were normal.
Dynamic CT of the abdomen was performed with a 128-
MDCT scanner (SOMATOM Definition AS, Siemens, Muenchen, 
Germany). After unenhanced images were obtained, dynamic 
three-phase imaging was begun after the start of injection 
of the contrast medium. Unenhanced CT revealed three high 
density lobulating masses with central calcification in the 
dome and segment 3 of the liver. The largest one, which was 
in segment 3 of the liver, was about 3 cm in diameter (Fig. 
1A). The attenuation of all three masses in the unenhanced 
CT was 88 HU (Hounsfield unit). The masses showed nearly 
the same attenuation in each phase compared to that of 
unenhanced CT (Fig. 1B-D). The differential diagnoses 
including multiple myeloma involvement, an inflammatory Korean J Radiol 12(3), May/Jun 2011 kjronline.org 383
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Fig. 1. 73-year-old woman with hepatic amyloidosis.
A. Unenhanced CT shows high density lobulating mass with central 
calcification (arrow) in segment 3 of liver. B-D. Mass shows very poor 
delayed contrast enhancement on arterial (B), portal venous (C) and 
delayed (D) phase image. E. US image during needle biopsy indicates 
mild heterogeneous echoic mass on segment 3 of liver (arrows). Korean J Radiol 12(3), May/Jun 2011 kjronline.org 384
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pseudotumor, and an unusual pattern of metastases from 
the other primary malignancy.
On ultrasonography (US), the masses showed mild 
heterogeneous echotexture (Fig. 1E). US-guided biopsy 
of the mass in segment 3 of the liver was performed with 
an 18 gauge gun-biopsy needle. Microscopically, diffuse 
amyloid deposits were found without viable hepatocyte (Fig. 
1F), and the Congo red stain was positive (Fig. 1G).
DISCUSSION
Amyloidosis is an uncommon disease that results from 
the extracellular deposition of amorphous, fibrillar protein. 
Amyloid is defined as a substance which stains positively 
with Congo red, exhibits apple green birefringence 
by polarization microscopy, shows aggregations of 
approximately 10 nm wide fibrils on electron microscopy, 
exhibits a ß-pleated sheet configuration on radiographic 
analysis, and shows resistance to proteases other than 
pronase (4). Progressive deposition of amyloid compresses 
and replaces normal tissue, and this leads to organ 
dysfunction and a wide variety of clinical syndromes, some 
of which have severe pathophysiological consequences (5).
Amyloidosis is usually observed in a systemic form 
although 10-20% of cases are localized (3). According to 
the World Health Organization’s classification, this is based 
on the structure of the variable fibrillar protein constituent 
(6). The vast majority of amyloidoses are either of the 
primary or secondary type (2). In primary amyloidosis, the 
characteristic fibrillar protein is a fragment of the variable 
immunoglobulin light (and/or rarely heavy) chain and 
thus is different from patient to patient. In contrast, the 
precipitating protein in secondary amyloidosis is always 
the amino acid terminus of the acute phase protein serum 
amyloid A (SAA) and is identical in all patients.
The primary amyloidosis has been associated with a 
monoclonal plasma cell dyscrasia, as at least 30% of those 
patients will eventually progress to multiple myeloma. 
Median survival time for patients with amyloidosis is 
1.5 years (7-9). Secondary amyloidosis is a result of 
chronic inflammatory disease (Crohn’s disease, adult 
or juvenile rheumatoid arthritis, Reiter’s syndrome, 
ankylosing spondylitis, familial Mediterranean fever, 
Sjögren’s syndrome, dermatomyositis, vasculitis, chronic 
osteomyelitis, tuberculosis, bronchiectasis, cystic fibrosis, 
systemic lupus erythematosus, and so on) and has a median 
survival of 4.5 years (10, 11). According to the above 
classification, our case belongs to the primary hepatic 
amyloidosis.
Amyloid protein deposition can be seen in a variety 
of organs, although it is more frequently observed in 
the gastrointestinal tract, kidney, and heart (1). In both 
primary and secondary amyloidosis, the most commonly 
involved organ system is the gastrointestinal system, with 
the colon being the most frequently involved organ (2). 
Although hepatic involvement is also common in patients 
with amyloidosis, the clinical manifestations of hepatic 
involvement are usually mild (5). Symptomatic involvement, 
including rupture, portal hypertension or hepatic failure, is 
rare (12-14). Hepatomegaly and a borderline abnormal liver 
function test are the most frequent findings in patients 
with hepatic amyloidosis (5).
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Fig. 1. 73-year-old woman with hepatic amyloidosis.
F, G. Microscopically, diffuse amyloid deposits are present without viable hepatocyte (F, Hematoxylin & Eosin staining, original magnification × 
200), and Congo red stain is positive (G).Korean J Radiol 12(3), May/Jun 2011 kjronline.org 385
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Radiological findings of hepatic involvement are non-
specific with heterogeneous echogenicity on US, diffuse 
or focal regions of decreased parenchymal attenuation 
with or without extensive calcification on CT or on MRI, 
a significantly increased signal intensity on T1-weighted 
images without a significantly altered signal intensity on 
T2-weighted images (14-18). Kim et al. (5) postulated 
that asymmetric hepatomegaly of a triangular shape with 
an apex at the falciform ligament and heterogeneous 
attenuation may help to differentiate amyloidosis from 
other infiltrative disease (5).
In our case, only three high density lobulating masses 
with central calcification were seen in the liver on 
unenhanced CT without asymmetrical hepatomegaly and 
heterogeneous attenuation of the liver in the dynamic 
phase. And, because of the progression deposition of 
the amyloid compress and the replacement of normal 
hepatocytes, the masses showed very poor delayed contrast 
enhancement in the dynamic phase. Secondary calcification 
of amyloid deposits is suggestive of amyloidosis, 
irrespective of the involved site (19). To our knowledge, 
amyloidosis involving the liver being presented as a mass 
has not been described previously.
Both the clinical and imaging presentations of 
amyloidosis are usually varied and non-specific, which 
may cause a delay in diagnosis and appropriate treatment 
changes. A biopsy is nearly always required for a proper 
diagnosis. We should consider that hepatic amyloidosis is 
usually presented as diffuse infiltration and hepatomegaly, 
but very rarely may appear as unusual focal masses.
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